Abbas Alibakhshi

Dr. Abbas Alibakhshi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
KSKiana Shahzamani
Kiana Shahzamani
FMFatemeh Mahmoudian
Fatemeh Mahmoudian
SAShahrzad Ahangarzadeh
Shahrzad Ahangarzadeh
MRMohammad Mehdi Ranjbar
Mohammad Mehdi Ranjbar
LBLeila Beikmohammadi
Leila Beikmohammadi
SJShaghayegh Haghjooy Javanmard
Shaghayegh Haghjooy Javanmard

4 January 2024 in Acta Virologica
Verified
Journal Article
Open access
AAAbbas Alibakhshi
Abbas Alibakhshi
ABArmina Alagheband Bahrami
Armina Alagheband Bahrami
EMElmira Mohammadi
Elmira Mohammadi
SAShahrzad Ahangarzadeh
Shahrzad Ahangarzadeh
MMMeysam Mobasheri
Meysam Mobasheri
Frequent, and sometimes more dangerous, mutations in SARS-CoV-2 indicate that a stronger strategy is needed to produce an effective vaccine—a vaccine that contains a wider range of virus factors and remains effective if one or more mutations have occurred in a part of the genome. In this study, four important virus proteins were used to make a multi-epitope protein vaccine. For this purpose, antigenic determinant of 4 proteins were selected and a protein structure was designed using 4 domains containing epitopes. After examining its antigenic potential, its three-dimensional structure was designed and then docked with immune system receptors. Finally, using the dynamic molecular (MD) simulation, complexes and interactions were investigated and their interaction energies were measured. The results of the study showed that the designed structure has good relative stability and interacts well with its receptors and can be used as a vaccine candidate for further studies.

1 August 2022 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
SRSoodabeh Rostami
Soodabeh Rostami
SGShima Gharibi
Shima Gharibi
HYHajar Yaghoobi
Hajar Yaghoobi
ZNZary Nokhodian
Zary Nokhodian
PSParisa Shoaei
Parisa Shoaei
AAAbbas Alibakhshi
Abbas Alibakhshi
Coronavirus disease 2019 (COVID-19) is the result of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Understanding molecular pathogenesis is an essential factor for the allocation of effective preventive measures and the development of targeted therapeutics against COVID-19. The genome of SARS-CoV-2 encodes structural and nonstructural proteins, which can be targets for compounds with potential therapeutic ability. On the other hand, the virus life cycle has stages susceptible to targeting by drug compounds. Many natural antiviral compounds have been studied and evaluated at the cellular and molecular levels with antiviral potential. Meanwhile, many studies over the past few months have shown that plant polysaccharides have a good ability to target proteins and stages of the virus life cycle. In this regard, in this review study, the virus specifications and infectious process and structural and functional components of SARSCoV- 2 will be reviewed, and then the latest studies on the effect of plant compounds with more focus on polysaccharides on viral targets and their inhibitory potential on the infectious process of COVID-19 will be discussed.

7 June 2023 in Research in Pharmaceutical Sciences
Verified
Journal Article
Open access
PPPardis Mohammadi pour
Pardis Mohammadi pour
KMKarim Mahnam
Karim Mahnam
MTMahsa Taherzadeh
Mahsa Taherzadeh
SAShahrzad Ahangarzadeh
Shahrzad Ahangarzadeh
AAAbbas Alibakhshi
Abbas Alibakhshi
EMElmira Mohammadi
Elmira Mohammadi
Background and purpose: Excitotoxicity in nerve cells is a type of neurotoxicity in which excessive stimulation of receptors (such as N-methyl-d-aspartate glutamate receptors (NMDAR)) leads to the influx of high-level calcium ions into cells and finally cell damage or death. This complication can occur after taking some of the plasminogen activators like tissue plasminogen activator and reteplase. The interaction of the kringle2 domain in such plasminogen activator with the amino-terminal domain (ATD) of the NR1 subunit of NMDAR finally leads to excitotoxicity. In this study, we assessed the interaction of two new chimeric reteplase, mutated in the kringle2 domain, with ATD and compared the interaction of wild-type reteplase with ATD, computationally. Experimental approach: Homology modeling, protein docking, molecular dynamic simulation, and molecular dynamics trajectory analysis were used for the assessment of this interaction. Findings/Results: The results of the free energy analysis between reteplase and ATD (wild reteplase: -2127.516 ± 0.0, M1-chr: -1761.510 ± 0.0, M2-chr: -521.908 ± 0.0) showed lower interaction of this chimeric reteplase with ATD compared to the wild type. Conclusion and implications: The decreased interaction between two chimeric reteplase and ATD of NR1 subunit in NMDAR which leads to lower neurotoxicity related to these drugs, can be the start of a way to conduct more tests and if the results confirm this feature, they can be considered potential drugs in acute ischemic stroke treatment.